Active Filter(s):
Details:
Based on research from Håvard Attramadal's lab at Oslo University Hospital, Tribune is developing a novel drug with a pan-antifibrotic mechanism of action targeting several fibrotic indications including diseases affecting the kidney, lung and liver.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Recipient: Tribune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing June 02, 2021
Details:
The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.
Lead Product(s): Emactuzumab
Therapeutic Area: Oncology Product Name: CXD301
Highest Development Status: Phase I Product Type: Large molecule
Recipient: SynOx Therapeutics
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 19, 2020